Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation. / Berendt, Louise; Håkansson, Cecilia; Bach, Karin Friis; Dalhoff, Kim; Andreasen, Per Buch; Petersen, Lene Birgitte Grejs; Andersen, Elin; Poulsen, Henrik Enghusen.

In: Ugeskrift for Laeger, Vol. 170, No. 33, 11.08.2008, p. 2437-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Berendt, L, Håkansson, C, Bach, KF, Dalhoff, K, Andreasen, PB, Petersen, LBG, Andersen, E & Poulsen, HE 2008, 'Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation', Ugeskrift for Laeger, vol. 170, no. 33, pp. 2437-9.

APA

Berendt, L., Håkansson, C., Bach, K. F., Dalhoff, K., Andreasen, P. B., Petersen, L. B. G., Andersen, E., & Poulsen, H. E. (2008). Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation. Ugeskrift for Laeger, 170(33), 2437-9.

Vancouver

Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LBG et al. Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation. Ugeskrift for Laeger. 2008 Aug 11;170(33):2437-9.

Author

Berendt, Louise ; Håkansson, Cecilia ; Bach, Karin Friis ; Dalhoff, Kim ; Andreasen, Per Buch ; Petersen, Lene Birgitte Grejs ; Andersen, Elin ; Poulsen, Henrik Enghusen. / Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation. In: Ugeskrift for Laeger. 2008 ; Vol. 170, No. 33. pp. 2437-9.

Bibtex

@article{bcce3df1d0e04a1dbdd2bb5ccc0257c6,
title = "Effekten af GCP-direktivet p{\aa} forskerinitierede kliniske laegemiddelfors{\o}g--sekundaerpublikation",
abstract = "Since 2004, adherence to Good Clinical Practice has been mandatory for all clinical drug trials. This was new to the investigator-initiated trials. Our study showed no association between the implementation of the Directive and investigator or industry-initiated trials. However, a steady decline was observed over the entire period. Presumably, the introduction of GCP did not entail a decline because of the presence of GCP units at university hospitals. Thus, researchers can conduct clinical drug trials under the same regulations as drug companies.",
author = "Louise Berendt and Cecilia H{\aa}kansson and Bach, {Karin Friis} and Kim Dalhoff and Andreasen, {Per Buch} and Petersen, {Lene Birgitte Grejs} and Elin Andersen and Poulsen, {Henrik Enghusen}",
year = "2008",
month = aug,
day = "11",
language = "Dansk",
volume = "170",
pages = "2437--9",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "33",

}

RIS

TY - JOUR

T1 - Effekten af GCP-direktivet på forskerinitierede kliniske laegemiddelforsøg--sekundaerpublikation

AU - Berendt, Louise

AU - Håkansson, Cecilia

AU - Bach, Karin Friis

AU - Dalhoff, Kim

AU - Andreasen, Per Buch

AU - Petersen, Lene Birgitte Grejs

AU - Andersen, Elin

AU - Poulsen, Henrik Enghusen

PY - 2008/8/11

Y1 - 2008/8/11

N2 - Since 2004, adherence to Good Clinical Practice has been mandatory for all clinical drug trials. This was new to the investigator-initiated trials. Our study showed no association between the implementation of the Directive and investigator or industry-initiated trials. However, a steady decline was observed over the entire period. Presumably, the introduction of GCP did not entail a decline because of the presence of GCP units at university hospitals. Thus, researchers can conduct clinical drug trials under the same regulations as drug companies.

AB - Since 2004, adherence to Good Clinical Practice has been mandatory for all clinical drug trials. This was new to the investigator-initiated trials. Our study showed no association between the implementation of the Directive and investigator or industry-initiated trials. However, a steady decline was observed over the entire period. Presumably, the introduction of GCP did not entail a decline because of the presence of GCP units at university hospitals. Thus, researchers can conduct clinical drug trials under the same regulations as drug companies.

M3 - Tidsskriftartikel

VL - 170

SP - 2437

EP - 2439

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 33

ER -

ID: 34090805